Dataset	LUAD	LUSC	
Total patients	477	467	
Age at diagnosis (y)	66(33-88)	66(39-85)	
Gender			
Male	220	346	
Female	257	121	
TNM stage			
I	253	222	
П	113	154	
III	78	81	
IV	25	6	
unknow	8	4	
T stage			
T1	159	104	
T2	254	274	
T3	43	68	
T4	18	21	
TX	3	-	
N stage			
NO	307	295	
N1	90	124	
N2	67	39	
N3	2	5	
NX and unknown	11	4	
M stage			
M0	313	387	
M1	24	6	
MX and unknown	140	74	
Survival status			
Dead	157	181	
Alive	320	286	

Dataset	GSE31210	GSE30219	GSE30219	GSE72094
Platform	GPL570	GPL570	GPL570	GPL15048
histology	LUAD	LUAD	LUSC	LUAD
Total patients	204	83	61	386
Age at diagnosis (y)	60(30-76)	60(44-86)	63(46-82)	66(38-89)
Gender				
Male	95	65	56	168
Female	109	18	5	218
Smoking				
Never	105	-	-	95
Ever	99	-	-	291
TNM stage				
Ι	162	-	-	246
II	42	-	-	65
III	-	-	-	56
IV+unknow	-	-	-	14+5
T stage				
T1	-	69	49	-
T2	-	12	6	-
Т3	-	2	4	-
T4	-	-	2	-
N stage				
NO	-	80	52	-
N1	-	3	9	-
Relapse				
Yes	54	27	38	-
No	150	56	22	-
NA	-	-	1	-
Survival status				
Dead	30	43	43	109
Alive	174	40	18	277

Table S2 Characteristics of LUAD and LUSC patients from GEO database




Figure S1 Correlation between NCAPG mRNA expression and clinicopathologic characteristics of LUSC patients. (A-D) The association of NCAPG mRNA with N stage, TNM stage, T stage and M stage of LUSC in TCGA dataset. (E-G) Association of NCAPG mRNA expression with T stage, N stage and relapse status of LUSC patients in GSE30219 dataset. **P <0.01.




Figure S2 Impact of NCAPG on survival of patients with LUSC. (A) K-M curve showing the impact of NCAPG on the OS of TCGA-LUSC patients. (B-C) K-M curves indicating the effect of NCAPG on OS and PFS of GSE30219-LUSC patients.




Figure S3 Calibration curve of the nomogram for patients with LUAD. The calibration curve showing the OS at one year (A), three years (B), and five years (C).




Figure S4 The volcano plot of DElncRNAs.




Figure S5 Plots showing GSEA results for LncRAN AC099850.3.